Hims & Hers Health (HIMS) Amortizatization of Intangibles (2020 - 2026)
Hims & Hers Health (HIMS) reported Amortizatization of Intangibles of $242000.0 for Q1 2026, down 65.08% on a YoY basis from $693000.0 in Q1 2025, and down 66.34% sequentially from $719000.0 in Q4 2025.
Hims & Hers Health (HIMS) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 7 years of Amortizatization of Intangibles data on file, last reported at $242000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 65.08% year-over-year to $242000.0; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (down 60.19% YoY), and the FY2025 full-year result was $2.0 million, down 53.34% from the prior year.
- Amortizatization of Intangibles fell to $242000.0 in Q1 2026, from $719000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.7 million in Q4 2023 to a low of -$971000.0 in Q1 2022.
- A 5-year average of $715823.5 and a median of $840000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles plunged 238.33% in 2022 and jumped 1333.33% in 2023, its largest moves.
- Tracing HIMS's Amortizatization of Intangibles over 5 years: stood at $840000.0 in 2022, then soared by 96.67% to $1.7 million in 2023, then slumped by 44.61% to $915000.0 in 2024, then dropped by 21.42% to $719000.0 in 2025, then plunged by 66.34% to $242000.0 in 2026.
- Business Quant data shows HIMS's Amortizatization of Intangibles at $242000.0 in Q1 2026, $719000.0 in Q4 2025, and $253000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | 242,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 242,000.00 |
| Mar 31, 2026 | 242,000.00 |
| Dec 31, 2025 | 719,000.00 |
| Dec 31, 2025 | 719,000.00 |
| Sep 30, 2025 | 253,000.00 |
| Sep 30, 2025 | 253,000.00 |
| Jun 30, 2025 | 367,000.00 |
| Jun 30, 2025 | 367,000.00 |
| Mar 31, 2025 | 693,000.00 |
| Mar 31, 2025 | 693,000.00 |
| Dec 31, 2024 | 915,000.00 |
| Dec 31, 2024 | 915,000.00 |
| Sep 30, 2024 | 1.16 Mn |
| Sep 30, 2024 | 1.16 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Dec 31, 2023 | 1.65 Mn |